Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease

Simon M. Helfgott, MD  |  Issue: October 2017  |  October 16, 2017


Simon M. Helfgott, MDSimon M. Helfgott, MD, is associate professor of medicine in the Division of Rheumatology, Immunology and Allergy at Harvard Medical School in Boston.

References

  1. Patel VG, Kalakuntla V, Fortson JK, et al. Stercoral perforation of the sigmoid colon: Report of a rare case and its possible association with nonsteroidal anti-inflammatory drugs. Am Surg. 2002 Jan;68(1):62–64.
  2. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2361–2371.
  3. Ramirez-Bermudez, J. Alzheimer’s disease: Critical notes on the history of a medical concept. Arch Med Res. 2012 Nov;43:595–599.
  4. George DR, Whitehouse PJ, D’Alton S, et al. Through the amyloid gateway. Lancet. 2012 Dec 8;380(9858):1986–1987.
  5. Dawkins E, Small DH. Insights into the physiological function of ß amyloid precursor protein: Beyond Alzheimer’s disease. J Neurochem. 2014 Jun;129(5):756–769.
  6. Goedert M, Spillantini MG, Crowther RA. A Brief history of tau. Clin Chem. 2015 Nov;61(11):1417–1418.
  7. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: Time, space and ‘wingmen.’ Nat Neurosci. 2015 Jun;18(6):800–806.
  8. Drachman DA. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement. 2014 May;10(3):372–380.
  9. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005 May 10;64(9):1553–1562.
  10. Omalu BI, DeKosky ST, Minster RL, et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005 Jul;57(1):128–134; discussion 128–134.
  11. McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 Jan;136(Pt 1):43–64.
  12. Roan NR, Sandi-Monroy N, Kohgadai N, et al. Semen amyloids participate in spermatozoa selection and clearance. Elife. 2017 Jun 27;6. pii: e24888.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Amyloidosisbraincase reportClinicaldementiaDiagnosismortalityneuronoutcomepatient careplaquerheumatologistrheumatology

Related Articles

    What Rheumatologists Need to Know about Identifying Amyloidosis

    June 1, 2013

    Although amyloidosis is not a rheumatic disease, rheumatologists may be the first to diagnose this life-threatening condition

    An Amylodosis Warning & New Drug Hope

    March 17, 2018

    SAN DIEGO—Treatments do exist that can improve the prospects of a patient with the rare disease amyloidosis, but only if clinicians keep the disease in mind and treat the patient before it’s too late, an expert said at the 2017 ACR/ARHP Annual Meeting this past November. He also discussed research that may be close to…

    Case Report: Does a Rapid-Onset Neck Mass Have Rheumatic Origins?

    September 17, 2019

    A 54-year-old African American man arrived at the emergency department with the acute onset of a tender mass on the left side of his neck. It had been getting progressively larger for the preceding two days. History & Examination His history included chronic right hip osteoarthritis with two surgeries performed five years prior. At his…

    Amyloidosis Is Often Underdiagnosed, Undertreated

    July 14, 2017

    CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences